LY83583

LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease^[1][2][3][4]. In Vitro:LY83583 (1 μM, 4 d) induces morphological changes characteristic of senescence and senescence-associated β-galactosidase (SA-β-gal) staining at pH 6 in early-passage HDFs^[1].
LY83583 (0.25-1.5 μM, 3 d) inhibits proliferation of early-passage HDFs, HCT116 and DLD1 colorectal cancer cell lines, MCF7 breast cancer cells and A-375 melanoma cells^[1].
LY83583 (1 μM, 24-36 h) almost completely blocks HDF entry into the S phase after release from G1 phase synchronization by confluence, and inhibits DNA synthesis detected by BrdU incorporation^[1].
LY83583 (1 μM, 3-6 h) induces p21 protein expression in HDFs^[1].
LY83583 (1 μM, 6 h) shifts the phosphorylation status of pRb in HDFs toward the hypophosphorylated form^[1].
LY83583 (1 μM, 2 h) inhibits SNP-induced cGMP synthesis in early-passage HDFs^[1].
LY-83583 (10 μM, 1 h) stimulates cytochalasin B-inhibitable [³H]3-O-methyl-D-glucose uptake in Clone 9 cells^[3].
In Vivo:LY83583 (10 μM, topical application via cranial window, 15 min) completely inhibits Nitroprusside (HY-B0564)-induced vasodilation of cerebral arterioles or calcitonin gene-related peptide (CGRP)-induced vasodilation in anesthetized cats^[2].
LY83583 (100 μg dissolved in 5 μL 20% DMSO, i.c.v., once) significantly and persistently decreases REMS duration and increases NREMS duration in male rats^[4].